Serially quantifying TERT rearrangement breakpoints in circulating tumor DNA enables minimal residual disease monitoring in patients with neuroblastoma.
Hollander JF, Szymansky A, Wünschel J, Astrahantseff K, Rosswog C, Thorwarth A, Thole-Kliesch TM, Chamorro Gonzalez R, Hundsdörfer P, Hauptmann K, Schmelz K, Gürgen D, Rogasch JMM, Henssen AG, Fischer M, Schulte JH, Eckert C, Eggert A, Lodrini M, Deubzer HE.
Hollander JF, et al. Among authors: fischer m.
Cancer Res Commun. 2025 Jan 6. doi: 10.1158/2767-9764.CRC-24-0569. Online ahead of print.
Cancer Res Commun. 2025.
PMID: 39760332
Free article.